Figure 2.

(A) mRNA expression of MDM2, CDK4, and HMGA2 on the basis of MDM2 co-amplification in METex14 and MET WT (y axis, log₂-transformed TPM; error bars represented interquartile range and median presented). (B) Oncoprint of MDM2, CDK4, and HMGA2 represented with mRNA expression levels. Red indicates higher expression and blue lower expression. (C) MET expression on the basis of METex14 mutation subtype (left) and MET co-amplification (right). (D) Ratios of METex14 mutation junction reads to WT junction reads in METex14/Amp+ versus METex14/Amp- (left) and Spearman correlation (right) of MET expression and ratio of METex14 junction reads to WT junction reads (gray dots: METex14/Amp-; red dots: METex14/Amp+). (E) Oncoprint of METex14 and MET co-amplification represented against MET expression and METex14 junction reads. Amp, amplification; METex14, MET exon 14; TPM, Trusted Platform Module; WT, wild type.